drugset / Trial / NCT02835729
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the regimen limiting toxicities (RLT) and recommended Phase 2 dose (RP2D) of indoximod in patients with newly diagnosed AML receiving remission induction chemotherapy with cytarabine and idarubicin.
Timeline
- Start
- 2016-07
- Primary completion
- 2019-10-25
- Completion
- 2019-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indoximod | Small molecule | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Idarubicin | Small molecule | — | — |